Holen Sie sich die Stockscreener-App
35.55
3.27%
1.125
Handel nachbörslich:
36.20
0.655
+1.84%
Schlusskurs vom Vortag:
$34.42
Offen:
$34.6
24-Stunden-Volumen:
565.37K
Relative Volume:
0.90
Marktkapitalisierung:
$1.14B
Einnahmen:
$4.85M
Nettoeinkommen (Verlust:
$-114.75M
KGV:
-10.94
EPS:
-3.25
Netto-Cashflow:
$-100.36M
1W Leistung:
+2.44%
1M Leistung:
-4.35%
6M Leistung:
+89.98%
1J Leistung:
+39.78%
1-Tages-Spanne:
$34.20
$36.60
1-Wochen-Bereich:
$33.34
$36.68
52-Wochen-Spanne:
$13.37
$40.16
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Vergleichen Sie DNTH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
35.55 | 1.37B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Dianthus Therapeutics (NASDAQ:DNTH) Earns Buy Rating from Analysts at Truist Financial - MarketBeat
Truist Securities initiates coverage on Dianthus Therapeutics stock with Buy rating - Investing.com
Can Dianthus Therapeutics Inc. stock hit analyst price targets2025 Top Decliners & Daily Growth Stock Investment Tips - newser.com
Published on: 2025-10-13 08:04:31 - newser.com
Published on: 2025-10-13 07:23:46 - newser.com
What analysts say about Dianthus Therapeutics Inc stockStock Split Announcements & Free Navigate Market With Precision - earlytimes.in
Is Dianthus Therapeutics Inc. (87E) stock at risk of policy regulationTake Profit & Fast Momentum Entry Tips - newser.com
When is the best time to exit Dianthus Therapeutics Inc.Earnings Trend Report & Weekly High Conviction Ideas - newser.com
How Dianthus Therapeutics Inc. stock benefits from global expansionTreasury Yields & Real-Time Stock Entry Alerts - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Is Dianthus Therapeutics Inc. (87E) stock a buy before new product rolloutQuarterly Growth Report & Fast Entry Momentum Trade Alerts - newser.com
Dianthus Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Performance Indicators - Markets Mojo
Volume spikes in Dianthus Therapeutics Inc. stock – what they meanMarket Sentiment Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Dianthus Therapeutics Inc. continue its uptrendInsider Buying & AI Enhanced Trading Signals - newser.com
Why Dianthus Therapeutics Inc. is moving todayTrade Risk Report & Free Long-Term Investment Growth Plans - newser.com
How Does Pritish Nandy Communications Ltd Compare to SP500 Over the Last 3 YearsFibonacci Extensions & Weekly Consultation With Financial Pros - earlytimes.in
What drives Dianthus Therapeutics Inc 87E stock priceDividend Growth Stocks & Free Expert Guidance For Growth - earlytimes.in
Advanced analytics toolkit walkthrough for Dianthus Therapeutics Inc.Market Sentiment Review & Safe Swing Trade Setup Alerts - newser.com
What Wall Street predicts for Dianthus Therapeutics Inc. stock priceQuarterly Earnings Report & Safe Capital Growth Tips - newser.com
What technical models suggest about Dianthus Therapeutics Inc.’s comebackJuly 2025 Rallies & Comprehensive Market Scan Reports - newser.com
Can Dianthus Therapeutics Inc. stock resist sector downturnsSell Signal & High Return Trade Opportunity Guides - newser.com
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.9%What's Next? - MarketBeat
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting - The Manila Times
Phase 2 Myasthenia Gravis Trial Results: Dianthus' Claseprubart Data to Be Unveiled at Major Conference - Stock Titan
Dianthus Therapeutics Hits New 52-Week High of $40.16 - Markets Mojo
What drives Okinawa Cellular Telephone Company OCU stock priceAnalyst Upgrades & High Profit Stock Alerts - earlytimes.in
Dianthus Therapeutics stock hits 52-week high at 40.0 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential - MSN
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target - MSN
Dianthus Therapeutics stock hits 52-week high at 40.0 USD - Investing.com
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year HighHere's Why - MarketBeat
What drives Dianthus Therapeutics Inc stock priceTechnical Resistance Breaks & Access Free Tools and Start Investing - earlytimes.in
Why retail investors pile into Dianthus Therapeutics Inc. stockPortfolio Growth Summary & Expert Approved Momentum Ideas - newser.com
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):